Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313

| Last Trade: | US$4.57 |
| Daily Change: | 0.03 0.66 |
| Daily Volume: | 111,107 |
| Market Cap: | US$196.650M |
November 13, 2025 November 13, 2025 September 23, 2025 September 02, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load